Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899496 · ClinicalTrials.gov registry record
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 54
- Enrollment target
NCT00899496: Completed study, sponsored by Wake Forest University Health Sciences.
NCT00899496 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00899496 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer. PURPOSE: This laboratory study is looking at an assay in determining cancer resistance in patients with metastatic cancer and in healthy participants.
Interventions
- OTHER physiologic testing
- OTHER immunological diagnostic method
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2005-09 |
| Est. Completion | 2009-10-23 |
What the finished NCT00899496 record still lists
NCT00899496 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which physiologic testing is the first listed.
NCT00899496 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00899496 about?
NCT00899496 is a clinical study titled "Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants". RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer. PURPOSE: This laboratory study is looking at an assay in determining cancer resistance in patients with metastatic cancer and in health...
What is the current status of trial NCT00899496?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2005-09. Estimated completion is 2009-10-23.
What interventions are being tested in trial NCT00899496?
The interventions under investigation include: physiologic testing (OTHER), immunological diagnostic method (OTHER).
Who is sponsoring clinical trial NCT00899496?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia